Thoratec sees greater market opportunity for HeartMate II

03/3/2010 | American City Business Journals

Thoratec plans to leverage the expanded FDA approval it secured for HeartMate II, a left ventricular pump, as a "destination therapy" for up to 100,000 U.S. patients with severe heart failure who are not candidates for transplantation. "We have always felt that the destination therapy market opportunity is greater than the bridge-to-transplant opportunities," Gary Burbach, Thoratec's president and CEO.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY